KIT and gastrointestinal stromal tumor: In this study, we showed that treatment of GIST xenograft lines with nilotinib resulted in a decrease in tumor growth, suggesting that nilotinib-mediated growth inhibition in GIST might be occurring through interference with the activity of KIT or PDGFRA signaling pathways.